Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

F. Aroldi, E. Elez, T. André, G. Perkins, H. Prenen, V. Popovici, P. Gallagher, J. Houlden, L. Collins, C. Roberts, C. Rolfo, F. Di Nicolantonio, M. Grayson, R. Boyd, K. Bettens, J. Delfavero, V. Coyle, M. Lawler, H. Khawaja, P. Laurent-Puig, M....

. 2025 ; 25 (1) : 658. [pub] 20250410

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, klinické zkoušky, fáze I

Perzistentní odkaz   https://www.medvik.cz/link/bmc25016127

Grantová podpora
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
602901 FP7 Health
C13749/A7261 Cancer Research UK - United Kingdom

BACKGROUND: Targeting RAS mutant (MT) colorectal cancer (CRC) remains a difficult challenge, mainly due to the pervasiveness of RAS/MEK-mediated feedback loops. Preclinical studies identified MET/STAT3 as an important mediator of resistance to KRAS-MEK1/2 blockade in RASMT CRC. This dose escalation/expansion study assessed safety and initial efficacy of the MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in RASMT advanced CRC patients. METHODS: In the dose escalation phase, patients with advanced solid tumours received binimetinib with crizotinib, using a rolling- 6 design to determine the maximum tolerable dose (MTD) and safety/tolerability. A subsequent dose expansion in RASMT CRC patients assessed treatment response. Blood samples for pharmacokinetics, MET biomarker and ctDNA analyses, and skin/tumour biopsies for pharmacodynamics, c-MET immunohistochemistry (IHC), MET in situ hybridisation (ISH) and MET DNA-ISH analyses were collected. RESULTS: Twenty patients were recruited in 3 cohorts in the dose escalation. The MTD was binimetinib 30 mg B.D, days 1-21 every 28 days, with crizotinib 250 mg O.D continuously. Dose-limiting toxicities included grade ≥ 3 transaminitis, creatinine phosphokinase increases and fatigue. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion. Pharmacokinetic and pharmacodynamic parameters showed evidence of target engagement. Across the entire study, the most frequent treatment-related adverse events (TR-AE) were rash (80.4%), fatigue (53.4%) and diarrhoea (51.8%) with grade ≥ 3 TR-AE occurring in 44.6%. Best clinical response within the RASMT CRC cohort was stable disease in seven patients (24%). Tumour MET super-expression (IHC H-score > 180 and MET ISH + 3) was observed in 7 patients (24.1%), with MET-amplification only present in 1 of these patients. This patient discontinued treatment early during cycle 1 due to toxicity. Patients with high baseline RASMT allele frequency had a significant shorter median overall survival compared with that seen for patients with low baseline KRASMT allele frequency. CONCLUSIONS: Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients. EudraCT-Number: 2014-000463 - 40 (20/06/2014: A Sequential Phase I study of MEK1/2 inhibitors PD- 0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type with aberrant c-MET).

Cardiff University and Velindre University NHS Trust Cardiff CF14 2 TL UK

Centre for Statistics in Medicine Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences University of Oxford Oxford UK

Department of GI Oncology Hôpital Européen Georges Pompidou 75015 Paris France

Department of Medical Oncology Sorbonne Université Hôpital Saint Antoine 75012 Paris France

Department of Medical Oncology University of Antwerp Antwerp University Hospital 2610 Wilrijk Belgium

Department of Molecular and Clinical Cancer Medicine University of Liverpool Ashton St Liverpool L69 3GE UK

Department of Oncology and University of Torino Candiolo Cancer Institute 10060 Candiolo TO Italy

Department of Oncology Molecular Biotechnology Center University of Torino Turin Italy

Department of Oncology University of Oxford Old Road Campus Research Building Roosevelt Drive Oxford OX3 7DQ UK

Faculty of Science RECETOX Masaryk University 625 00 Brno Czech Republic

Genomics Diagnostics and Genomics Group Agilent Technologies 1831 Diegem Belgium

IFOM ETS the AIRC Institute of Molecular Oncology Milan Italy

Institut National de La Sante Et de La Recherche Medicale Universite Paris Descartes 75006 Paris France

Northern Ireland Cancer Centre Belfast Health and Social Care Trust Belfast BT9 7 AB UK

Oncology Clinical Trials Office Department of Oncology University of Oxford Oxford OX3 7LJ UK

Patrick G Johnston Centre for Cancer Research School of Medicine Dentistry and Biomedical Science Queen's University Belfast Belfast BT9 7AE UK

Royal College of Surgeons in Ireland University of Medicine and Health Sciences 123 St Stephen's Green Dublin Ireland

Vall d'Hebron University Hospital and Institute of Oncology 08035 Barcelona Spain

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016127
003      
CZ-PrNML
005      
20250731091534.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-025-14068-1 $2 doi
035    __
$a (PubMed)40211189
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Aroldi, Francesca $u Department of Oncology, University of Oxford, Old Road Campus Research Building Roosevelt Drive, Oxford, OX3 7DQ, UK
245    12
$a A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC) / $c F. Aroldi, E. Elez, T. André, G. Perkins, H. Prenen, V. Popovici, P. Gallagher, J. Houlden, L. Collins, C. Roberts, C. Rolfo, F. Di Nicolantonio, M. Grayson, R. Boyd, K. Bettens, J. Delfavero, V. Coyle, M. Lawler, H. Khawaja, P. Laurent-Puig, M. Salto-Tellez, TS. Maughan, J. Tabernero, R. Adams, R. Jones, BT. Hennessy, A. Bardelli, M. Peeters, MR. Middleton, RH. Wilson, S. Van Schaeybroeck, MErCuRIC Trial Consortium
520    9_
$a BACKGROUND: Targeting RAS mutant (MT) colorectal cancer (CRC) remains a difficult challenge, mainly due to the pervasiveness of RAS/MEK-mediated feedback loops. Preclinical studies identified MET/STAT3 as an important mediator of resistance to KRAS-MEK1/2 blockade in RASMT CRC. This dose escalation/expansion study assessed safety and initial efficacy of the MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in RASMT advanced CRC patients. METHODS: In the dose escalation phase, patients with advanced solid tumours received binimetinib with crizotinib, using a rolling- 6 design to determine the maximum tolerable dose (MTD) and safety/tolerability. A subsequent dose expansion in RASMT CRC patients assessed treatment response. Blood samples for pharmacokinetics, MET biomarker and ctDNA analyses, and skin/tumour biopsies for pharmacodynamics, c-MET immunohistochemistry (IHC), MET in situ hybridisation (ISH) and MET DNA-ISH analyses were collected. RESULTS: Twenty patients were recruited in 3 cohorts in the dose escalation. The MTD was binimetinib 30 mg B.D, days 1-21 every 28 days, with crizotinib 250 mg O.D continuously. Dose-limiting toxicities included grade ≥ 3 transaminitis, creatinine phosphokinase increases and fatigue. Thirty-six RASMT metastatic CRC patients were enrolled in the dose expansion. Pharmacokinetic and pharmacodynamic parameters showed evidence of target engagement. Across the entire study, the most frequent treatment-related adverse events (TR-AE) were rash (80.4%), fatigue (53.4%) and diarrhoea (51.8%) with grade ≥ 3 TR-AE occurring in 44.6%. Best clinical response within the RASMT CRC cohort was stable disease in seven patients (24%). Tumour MET super-expression (IHC H-score > 180 and MET ISH + 3) was observed in 7 patients (24.1%), with MET-amplification only present in 1 of these patients. This patient discontinued treatment early during cycle 1 due to toxicity. Patients with high baseline RASMT allele frequency had a significant shorter median overall survival compared with that seen for patients with low baseline KRASMT allele frequency. CONCLUSIONS: Combination binimetinib/crizotinib showed a poor tolerability with no objective responses observed in RASMT advanced CRC patients. EudraCT-Number: 2014-000463 - 40 (20/06/2014: A Sequential Phase I study of MEK1/2 inhibitors PD- 0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type with aberrant c-MET).
650    _2
$a lidé $7 D006801
650    12
$a kolorektální nádory $x farmakoterapie $x genetika $x patologie $7 D015179
650    12
$a benzimidazoly $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D001562
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a krizotinib $x aplikace a dávkování $x škodlivé účinky $7 D000077547
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a mutace $7 D009154
650    _2
$a protoonkogenní proteiny c-met $x antagonisté a inhibitory $x genetika $7 D019859
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $x farmakokinetika $x aplikace a dávkování $7 D000971
650    _2
$a dospělí $7 D000328
650    _2
$a MAP kinasa-kinasa 1 $x antagonisté a inhibitory $7 D048369
650    _2
$a inhibitory proteinkinas $x aplikace a dávkování $x škodlivé účinky $7 D047428
650    _2
$a MAP kinasa-kinasa 2 $x antagonisté a inhibitory $7 D048370
650    _2
$a maximální tolerovaná dávka $7 D020714
650    _2
$a Ras proteiny $x genetika $7 D018631
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze I $7 D017426
700    1_
$a Elez, Elena $u Vall d'Hebron University Hospital and Institute of Oncology (VHIO), 08035, Barcelona, Spain
700    1_
$a André, Thierry $u Department of Medical Oncology, Sorbonne Université, Hôpital Saint Antoine, 75012, Paris, France
700    1_
$a Perkins, Geraldine $u Department of GI Oncology, Hôpital Européen Georges-Pompidou, 75015, Paris, France
700    1_
$a Prenen, Hans $u Department of Medical Oncology, University of Antwerp/Antwerp University Hospital, 2610, Wilrijk, Belgium
700    1_
$a Popovici, Vlad $u Faculty of Science, RECETOX, Masaryk University, 625 00, Brno, Czech Republic
700    1_
$a Gallagher, Peter $u Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, BT9 7 AB, UK $u Patrick G. Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, BT9 7AE, UK
700    1_
$a Houlden, Jennifer $u Oncology Clinical Trials Office (OCTO), Department of Oncology, University of Oxford, Oxford, OX3 7LJ, UK
700    1_
$a Collins, Linda $u Oncology Clinical Trials Office (OCTO), Department of Oncology, University of Oxford, Oxford, OX3 7LJ, UK
700    1_
$a Roberts, Corran $u Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
700    1_
$a Rolfo, Christian $u Department of Medical Oncology, University of Antwerp/Antwerp University Hospital, 2610, Wilrijk, Belgium
700    1_
$a Di Nicolantonio, Federica $u Department of Oncology &, University of Torino, Candiolo Cancer Institute, 10060, Candiolo, TO, Italy
700    1_
$a Grayson, Margaret $u Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, BT9 7 AB, UK
700    1_
$a Boyd, Ruth $u Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, BT9 7 AB, UK
700    1_
$a Bettens, Karolien $u Genomics, Diagnostics and Genomics Group, Agilent Technologies, 1831, Diegem, Belgium
700    1_
$a Delfavero, Jurgen $u Genomics, Diagnostics and Genomics Group, Agilent Technologies, 1831, Diegem, Belgium
700    1_
$a Coyle, Victoria $u Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, BT9 7 AB, UK $u Patrick G. Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, BT9 7AE, UK
700    1_
$a Lawler, Mark $u Patrick G. Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, BT9 7AE, UK
700    1_
$a Khawaja, Hajrah $u Patrick G. Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, BT9 7AE, UK
700    1_
$a Laurent-Puig, Pierre $u Institut National de La Sante Et de La Recherche Medicale (INSERM), Universite Paris Descartes, 75006, Paris, France
700    1_
$a Salto-Tellez, Manuel $u Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, BT9 7 AB, UK $u Patrick G. Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, BT9 7AE, UK
700    1_
$a Maughan, Tim S $u Department of Oncology, University of Oxford, Old Road Campus Research Building Roosevelt Drive, Oxford, OX3 7DQ, UK $u Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Ashton St, Liverpool, L69 3GE, UK
700    1_
$a Tabernero, Josep $u Vall d'Hebron University Hospital and Institute of Oncology (VHIO), 08035, Barcelona, Spain
700    1_
$a Adams, Richard $u Cardiff University and Velindre University NHS Trust, Cardiff, CF14 2 TL, UK
700    1_
$a Jones, Robert $u Cardiff University and Velindre University NHS Trust, Cardiff, CF14 2 TL, UK
700    1_
$a Hennessy, Bryan T $u Royal College of Surgeons in Ireland University of Medicine and Health Sciences, 123 St. Stephen's, Green, Dublin, Ireland
700    1_
$a Bardelli, Alberto $u Department of Oncology, Molecular Biotechnology Center, University of Torino, Turin, Italy $u IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy
700    1_
$a Peeters, Marc $u Department of Medical Oncology, University of Antwerp/Antwerp University Hospital, 2610, Wilrijk, Belgium
700    1_
$a Middleton, Mark R $u Department of Oncology, University of Oxford, Old Road Campus Research Building Roosevelt Drive, Oxford, OX3 7DQ, UK
700    1_
$a Wilson, Richard H $u Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, BT9 7 AB, UK $u Patrick G. Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, BT9 7AE, UK
700    1_
$a Van Schaeybroeck, Sandra $u Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, BT9 7 AB, UK. s.vanschaeybroeck@qub.ac.uk $u Patrick G. Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, BT9 7AE, UK. s.vanschaeybroeck@qub.ac.uk
710    2_
$a MErCuRIC Trial Consortium
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 25, č. 1 (2025), s. 658
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40211189 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091528 $b ABA008
999    __
$a ok $b bmc $g 2366753 $s 1253252
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 25 $c 1 $d 658 $e 20250410 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a 602901 $p FP7 Health
GRA    __
$a C13749/A7261 $p Cancer Research UK $2 United Kingdom
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace